Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events
Source · ClinicalTrials.gov: elamipretide
TLDR
ClinicalTrials.gov lists EMBRACE-STEMI, a Phase 2a trial of elamipretide, as completed. The study assessed safety, tolerability, and efficacy for reducing reperfusion injury in patients with a first acute anterior-wall STEMI; the excerpt provides no results.
- 01The multinational, multicenter trial was randomized, double-blind, and placebo-controlled.
- 02Elamipretide, also called MTP-131 or Bendavia, was studied alongside standard-of-care therapy.
- 03Completion status is reported, but safety and efficacy findings are not provided.
Why it matters Editorial
The trial evaluated elamipretide for reperfusion injury after an acute heart attack, but the excerpt does not establish whether it was effective or safe.
Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.
ClinicalTrials.gov: elamipretide
ClinicalTrials.gov: elamipretide
ClinicalTrials.gov: elamipretide
ClinicalTrials.gov: elamipretide